For patients with relapsed/refractory large B-cell lymphoma, access to lifesaving CD19-directed chimeric antigen receptor (CAR) T-cell therapy may be limited by post-infusion monitoring protocols ...
Researchers sought to determine whether patients who are functional high-risk had a worse prognosis even without having traditional high-risk features.